33results about How to "Side effect" patented technology

An application of a high-intensity focused ultrasound system to treatment of essential hypertension. A treatment process includes: conducting ultrasonic positioning measurement on both sides of perirenal fat tissue of a patient, setting a therapeutic window and parameters of the system, and setting corresponding power parameter of the system, so as to make local temperature of the tissue during treatment reach 40-70° C., wherein treatment portions are both sides, and treatment scope is one third to all of the whole tissue; starting the system to treat one side of the tissue according to the set parameters and then the other. By treating a secondary center for regulating the activity of a whole-body sympathetic system, the activity of the whole-body sympathetic system can be reduced, so that the blood pressure level of the patient can be reduced, and fewer kinds and smaller dosage of antihypertensive drugs can be taken or ceased.

A high-strength, biodegradable, organic polymer/inorganic particle composite material for bone fixation, which is prepared by mixing and dispersing a biocompatible, inorganic fine or ultrafine particle in an organic monomer and then polymerizing the organic monomer and thus exhibits remarkably improved mechanical strength, and also to a high-strength, biodegradable, organic polymer/inorganic particle composite material prepared thereby is disclosed. More particularly, the a high-strength, biodegradable, organic polymer/inorganic particle composite material for bone fixation is prepared by mixing and dispersing a calcium phosphorus compound or a calcium aluminate compound in a biodegradable organic monomer, at the amount of 0.5 to 60% by weight; and polymerizing the biodegradable organic monomer; and then forming the polymerized material into a desired shape. The synergistic, reinforcing effect of the inorganic fine particle is increased, so that the high-strength material for bone fixation can be prepared. Also, the biocompatible fine particle is used, so that a long-term side effect can be reduced.

Embodiments provide an apparatus, system, kit and method for in vivo measurement of blood oxygen saturation (BAS). One embodiment provides an implantable apparatus for measuring BAS comprising a housing, emitter, detector, processor and power source. The housing is configured to be injected through a tissue penetrating device into a target tissue site (TS). The emitter is configured to emit light into the TS to measure BAS, the emitted light having at least one wavelength (LOW) whose absorbance is related to a BAS. The detector is configured to receive light reflected from the TS, detect light at the LOW and generate a detector output signal (DOS) responsive to an intensity of the detected light. The processor is operably coupled to the detector and emitter to send signals to the emitter to emit light and receive the DOS and includes logic for calculating a BAS and generate a signal encoding the BAS.

The present invention provides a method of treating conditions associated with iron and calcium overload comprising administering an effective amount of dexrazoxane or a non-dexrazoxane compound of formula (IA), (IB), or (IC) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.

The embodiments herein provide a powdered composition of natural substances for controlling deficiencies in polypeptide alpha and beta hemoglobin chains and a diet plan for treating thalassemia patient. The composition comprises passargad powder, pars powder, purgative material, fumigation material, snuffing material, vinegar syrup and parsomash powder. The passargad powder is a stomach tonic and acts as anti-parasitic, anti-diarrheal, anti-dysentery, anti-bloating and anti-heartburn agents. The pars powder comprises sprouted grains for providing nutrition to cells. The purgative material is body purifier or detoxification agent and helps in motion and bowl movement. The vapor/fumigation material softens and reduces stickiness of sputum and removes sputum. The snuff helps in sneezing and removal of sputum. The vinegar syrup breaks down fat and removes toxins. The parsomash is an detoxification agent. The composition and dietary plan eliminates the need of bone marrow transplant, blood transfusion and defroxamin in thalassemia patients.

The pharmaceutical preparation for oral contraception has 28 daily dosage units, of which at least 21 daily dosage units each contain from 1.5 mg to 2 mg of dienogest and from 0.015 mg to 0.02 mg of ethinyl estradiol together in a pharmaceutically acceptable carrier. Seven or fewer daily dosage units contain no effective ingredient. Each daily dosage unit can be a film tablet for oral administration, which has a tablet core and film coating on the tablet core. At least 30% of the dienogest is released from the tablet core preferably in a delayed manner after more than 30 minutes, while at least 70% of the dienogest and ethinyl estradiol are released from the film coating preferably in 30 minutes, as determined by a standard dissolution test.

A collagen peptide mixture containing three or more kinds selected from Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, chemically-modified substances thereof and pharmaceutically acceptable salts thereof, and at least one peptide selected from the group consisting of Glu-Hyp-Gly, Glu-Hyp, Leu-Hyp-Gly, Pro-Ala, Ser-Hyp, Ala-Hyp-Gly, Pro-Hyp-Gly, Leu-Hyp, Ile-Hyp, Ser-Hyp-Gly, Gly-Pro-Hyp, (Pro-Hyp-Gly)₅, Pro-Hyp, Hyp-Gly, Pro-Gly, Pro-Pro and Ala-Hyp or a chemically-modified substance thereof or a pharmaceutically acceptable salt thereof have DPPTV inhibitory activity and/or GLP-1 secretion accelerating activity, and hence are effective as a therapeutic or preventive agent or the like for diabetes.

Catalytic system for polymerization of lower alpha alkene including a selectivity control agent which consists of naturally derived pure isomers of tartrates such as esters of (2-R,3-R)-dihydroxy-butane-1,4dicarboxylic acid or (2-S,3-S)-dihydroxybutane-1,4-dicarboxylic acid. The molar ratio of the optically pure isomers of the tartrates to titanium being 0.0375 to 1.5.

A negative-balanced isolated pelvic perfusion method, in which a drug is administered into the closed pelvis while keeping the volume of suction from the vein larger than that of injection into the artery, does not require allogeneic blood transfusion. A perfusion device is for recovering a liquid containing a drug and/or blood from a tube connecting to the inferior vena cava and for injecting the liquid obtained into a tube connecting to the artery, provided with a unit for closing the inside of the pelvis by including a unit for blocking the artery from the heart to the pelvis, a unit for blocking the inferior vena cava from the pelvis to the heart, and a unit for blocking a blood flow from the pelvis to the lower limbs. The perfusion device is provided with a pelvic perfusion unit equipped with a reservoir, an autotransfusion unit, and a dialysis unit.

Described herein are compositions and methods for using these compositions in the treatment of cancer, tumors, and tumor-related disorders in a subject.

An application of a radiofrequency catheter ablation system to treatment of essential hypertension. The treatment process is under ultrasonic guidance, an electrode needle is made to penetrate into target tissue of a patient, electrification is conducted to start ablation, the needle is withdrawn or made to penetrate into the other side of the target tissue for target ablation after reaching ablation temperature and duration time, and overall ablation treatment is completed. The system can treat a secondary center for regulating the activity of a whole-body sympathetic system to reduce its activity, thus, the blood pressure level of a patient can be reduced, and fewer kinds and smaller dosage of antihypertensive drugs taken or ceased altogether. By treating the secondary center, the activity of the whole-body sympathetic system, insulin resistance and whole-body fibrosis is reduced, and other diseases characterized in activity abnormity of the sympathetic system might be treated too.

Provided are a functional food or pharmaceutical composition or a method for preventing, alleviating or treating hyperphosphatemia and chronic kidney disease and treating chronic kidney disease using the composition comprising Lactobacillus sp. KCCM 11826P having excellent phosphorus-absorbing ability.

The invention provides a method for the purification of complexed ²²⁷Th from a mixture comprising complexed ²²⁷Th and ²²³Ra (complexed or in solution), said method comprising: i) preparing a first solution comprising a mixture of complexed ²²⁷Th ions and ²²³Ra ions in a first aqueous buffer; ii) loading said first solution onto a separation material; iii) eluting complexed ²²⁷Th from said separation material whereby to generate a second solution comprising complexed ²²⁷Th; iv) Optionally rinsing said separation material using a first aqueous washing medium; The invention additionally provides a purified ²²⁷Th solution, a pharmaceutical product and its use in treatment of disease such as cancer and a kit for generation of such a product.

This invention relates to compositions and methods for achieving and maintaining maximal analgesic effect following intra-articular administration of corticosteroid formulations. The invention also describes extended release, e.g., controlled- or sustained-release corticosteroid formulations, including extended release, e.g., controlled- or sustained-release formulations of triamcinolone acetonide (TCA), fluticasone propionate, cortisol, ciclesonide (monopropionate), beclometasone diproprionate, dexamethasone, flunisolide, budesonide, desisobutyryl-ciclesonide, and/or mometasone furoate, that produce a maximal analgesic effect greater than the acute analgesic effect provided by standard corticosteroid suspensions, including non-extended release corticosteroid suspensions, and that are also associated with a clinically insignificant effect on endogenous cortisol production following administration, for example, intra-articular, intrathecal, epidural, intra-bursal, or other local administration.

A securement device for securing a drum head upon a drum shell or body through a tension rod, including a lug assembly that not only allows a downward pull on and hence tightening of the associated tension rod, but also provides for three additional parameters of adjustment of the position and aspect of the lower end of the tension rod relative to the associated drum shell.

The present invention provides systems, compositions and methods for treatment of dopaminergic disorders (e.g., Parkinson's disease) using the combination of a first compound that inhibits a voltage-gated calcium channel of the type Ca_v1.3 (e.g., a dihydropyridine such as isradipine), and a second compound that is monoamine oxidase inhibitor and/or is a nitric oxide synthase inhibitor (e.g., rasagiline or derivative thereof).

The invention relates to uses and methods of treating migraine with a plant extract that includes a therapeutically effective dose of a mixture of flavonoids rich in proanthocyanidis. Methods and uses are described to substantially prevent migraine from occurring; reduce the frequency of migraine or reduce the severity of migraine symptoms.

The present invention features methods of delivering corticosteroids or metabolites thereof for treating inflammatory conditions otherwise difficult to cure with topical administration.